Palm Oil and AI: An Odd Pairing I’m Watching, Not Buying
Malaysia’s data centres are straining the water supply, and a palm oil coolant might help. It’s made me look twice at IOI — but I’m not buying yet.
Malaysia’s data centres are straining the water supply, and a palm oil coolant might help. It’s made me look twice at IOI — but I’m not buying yet.
July looked like a modest 1.49% bounce back from June’s rough month. Underneath it, one part of the portfolio did all the work while everything else quietly got worse — and three stocks reacted to good news in three completely different ways.
Two very different blow-ups — a hedge fund forced into liquidation, Korean retail investors wrecked by leveraged ETFs — left me with the same takeaway. I walk through the questions I actually ask myself before putting money into a fund, using my own Hamilton Lane position as the example.
The Nasdaq-100 and South Korea’s KOSPI both hit correction territory this week — then bounced hard, one much faster than the other. Neither move told me anything. So instead of guessing what happens next, I scored every holding in my portfolio using five simple questions, weighted by market value, and found out my biggest position wasn’t as safe as I thought.
Gold queues at BullionStar, $2M condo FOMO, silver crashing 38% in four months — everyone’s rushing into hard assets in 2026. Here’s why most of them are buying the wrong things at the wrong time, and what I’m doing with cash instead.
My April 2026 portfolio returned +9.6%, now 4.2 percentage points ahead of the S&P 500 YTD. Healthcare led, Industrials lagged, and five positions reported earnings in 24 hours. Here’s what I’m watching going into May.
The UAE just left OPEC — the third-largest member walking out for the first time. Here’s why oil spikes near-term, why I think prices crash once the war ends, and why buying gold at $4,630 is the wrong trade today.
HSBC’s new 7% Perpetual AT1 bond looks attractive at first glance. Here’s why I passed — the macro environment, a 2-point banker’s spread, and the CoCo structure that most private investors don’t fully understand.
March was rough — portfolio down 3.6%, but still beating the S&P 500’s 5.1% drop. OVID surged 36%, WeRide delivered, and Pony AI got punished on earnings. Here’s my full March breakdown and Q1 strategy reset.
I bought Novo Nordisk (NYSE: NVO) call options betting on a V-shape recovery after earnings. They’re now worth almost nothing. In this post I walk through what happened, why I still hold the stock, and why my view is a hold for now — not a buy, not a sell.